(Yicai Global) Feb. 8 -- A unit under Tianjin Chase Sun Pharmaceutical Co. has received a quality certificate from authorities in Europe for etomidate, an anesthetic agent, thereby boosting the firm's hopes of developing the drug in the global market.

Huzhou-based Zhanwang Pharmaceutical Co. received a Certificate of Suitability in line with the European Directorate for the Quality of Medicines & HealthCare, which is valid for five years, the firm said in a statement.

The CEP certificate boosts the firm's professional brand image and expands its prospects in the high-end market worldwide.

Etomidate is an intravenous hypnotic anesthetic and a safe anesthesia induction drug.